AtriCure, Inc. announced robust financial results for the fourth quarter of 2025, with worldwide revenue increasing by 13.1% year-over-year to $140.5 million. The company also reported a net income of $1.8 million and a positive adjusted EBITDA of $19.9 million, reflecting strong execution and continued momentum across its business.
Fourth Quarter 2025 worldwide revenue increased by 13.1% to $140.5 million.
The company achieved a net income of $1.8 million for the fourth quarter of 2025, a significant improvement from a net loss in the prior year.
Adjusted EBITDA for Q4 2025 was $19.9 million, up from $12.7 million in Q4 2024.
Gross margin improved to 75.0% in Q4 2025, an increase of 45 basis points from the previous year, driven by a more favorable product mix.
Management projects continued strong growth and profitability for the full year 2026, with anticipated revenue between $600 million and $610 million and positive adjusted EBITDA.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance